Delving into the Latest Updates on Ascension Healthcare Development Ltd. with Synapse

概览

关联

1

项与 Ascension Healthcare Development Ltd. 相关的药物

Recombinant Human Coagulation Factor VIII Liposomal(Ascension Healthcare)

重组人凝血因子Ⅷ脂质体(Ascension Healthcare)

靶点

F10

作用机制

F10刺激剂

在研机构-

原研机构

Ascension Healthcare Development Ltd.

在研适应症-

非在研适应症

血友病A

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Ascension Healthcare Development Ltd. 相关的临床试验

NCT04592692

/ Unknown status临床2期

A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Administered Intravenously to Severe Haemophilia A Patients With and Without Inhibitors to FVIII

The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to FVIII.

开始日期2019-12-23

申办/合作机构

Ascension Healthcare Development Ltd.

100 项与 Ascension Healthcare Development Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Ascension Healthcare Development Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Ascension Healthcare Development Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Ascension Healthcare Development Ltd. 相关的转化医学

登录后查看更多信息